Other targets in phase III trials included IL-4/13 (n = 1 for atopic dermatitis, prurigo nodularis, and CSU, respectively), IL-5 (n = 1 for bullous pemphigoid), and IgE (n = 1 for CSU). Here, IL5 is linked to atopic eczema.